Revelation Biosciences, Inc. (REVB)
1.01
0.00 (0.00%)
USD |
NASDAQ |
Sep 09, 11:22
Revelation Biosciences Debt to Equity Ratio : 0.0735 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0735 |
| March 31, 2026 | 0.0584 |
| December 31, 2025 | 0.0843 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | -0.1688 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 9.766 |
| June 30, 2020 | 4.598 |
| March 31, 2020 | |
| December 31, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Shuttle Pharmaceuticals Holdings, Inc. | 0.064 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Agenus, Inc. | -1.458 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Amgen, Inc. | 4.903 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 12.50M |
| Total Liabilities (Quarterly) | 2.431M |
| Shareholders Equity (Quarterly) | 10.07M |
| Current Ratio | 6.214 |
| Net Debt Paydown Yield | -3.68% |